Cooperative Breast Cancer Tissue Resource (CBCTR)

描述（由申请人提供） 具体目标 合作乳腺癌组织资源（CBCTR）的开发始于1993年，以响应国家癌症研究所和美国四个站点之间的合作协议，向生物医学研究界提供乳腺癌组织，用于研究肿瘤预后的临床标志物，并评估基于这些标志物的有前途的诊断测试。当前的申请是对CBCTR重新申请三年资助的请求信的回应。 具体而言，这四个机构将单独和共同 1.继续从CBCTR档案中向社区研究人员提供标本。所提供的材料将主要以组织微阵列的形式出现，在一张或两张载玻片上包含数百例病例的标本。然而，当特定实验只能用乳腺癌材料进行时，CBCTR将保留满足一些个别病例的乳腺癌材料切片请求的能力。 2.继续收集和更新每个研究中心病例的临床和结局数据，以确保每个病例的材料最准确和最新。这种审查将利用自动化的数据来源，但也可能需要审查大量的主要来源：这些妇女的医疗记录。 3.补充研究人员使用过的案例的CBCTR。CBCTR目前是一个有限的资源，没有随着新案件的增加而得到补充。它被设计成供其客户癌症研究人员使用，并且不可避免地被消耗。另一方面，如果资金到位，并且国家癌症研究所决定在CBCTR中保留大量具有代表性的乳腺癌混合病例，则每个研究中心可以通过自1993年以来诊断的新病例来补充资源，1993年最初的申请获得资金，此后几乎没有新病例。

DESCRIPTION (provided by applicant) Specific Aims The Cooperative Breast Cancer Tissue Resource (CBCTR) was developed, starting in 1993, in response to a cooperative agreement between the National Cancer Institute and four sites in the United States to provide breast cancer tissue to the biomedical research community for the study of clinical markers of tumor prognosis and the evaluation of promising diagnostic tests based on these markers. The current application is a response to a Letter Request for Applications for Recompetition of the CBCTR for a further three years of funding. Specifically, these four institutions individually and together will 1. Continue the provision of specimens to researchers in the community from the files of the CBCTR. The material provided will be mainly in the form of Tissue Microarrays that incorporate specimens from hundreds of cases on one or two slides. The CBCTR will, however, retain the ability to fill requests for sections of breast cancer material from a number of individual cases when the particular experiment can only be done with such material. 2. Continue the collection and updating of clinical and outcome data on each site's cases to assure the most accurate and contemporary material for each case. Such review will exploit automated sources of data but will also likely require review of a considerable number of primary sources: the medical records of these women. 3. Replenish the CBCTR for the cases that have been used by researchers. The CBCTR is currently a finite resource and is not being replenished with the addition of new cases. It has been designed to be used and, inevitably, depleted by its client cancer researchers. On the other hand, if funding becomes available and the National Cancer Institute decides to maintain a large and representative mixture of breast cancers in the CBCTR, each site can replenish the Resource by accrual of new cases diagnosed since 1993, when the original application was funded and after which few new cases were accrued.